Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ELAN SALES RISE 44% TO $135.8 MIL. IN FY 1993 PACED BY CARDIZEM CD, VERELAN

Executive Summary

Elan fiscal year sales jumped 44% to $135.8 mil. and earnings spiraled up 62.5% to $32.3 mil. for the 12 months ended March 31. Elan Chairman Donald Panoz said May 4 that the "highlight of the year has been the success of the U.S. market for Cardizem CD," which Elan licenses to Marion Merrell Dow. Lederle, which licenses Verelan, "increased" that product's sales, Panoz noted. He added that the downturn of nicotine patch sales in the U.S. has been "somewhat offset by launches in new markets." Elan's patch product, marketed in the U.S. by Lederle as ProStep, is available in 12 countries. Elan announced that it has exercised its option to acquire the outstanding shares of Drug Research Corp., which is a vehicle to develop Elan's ETDAS electrotransport and IPDAS gastrointestinal absorption technologies. As a result, Elan will take a one-time charge of $82.5 mil. against first quarter FY 1994 earnings. DRC was formed in 1990 via a unit rights offering that raised $43.2 mil. Panoz said the board felt that it was an "appropriate" time to acquire DRC in light of the "imminent" filing of an NDA for Naprelan, a once-daily naproxen using an IPDAS formulation. Forest Labs reported a 19.3% sales increase for the year ended March 31 to $296.4 mil. Twelvemonth earnings rose 29.7% to $64.3 mil. For the fourth quarter, sales were ahead 18.2% at nearly $77 mil. and net income increased 28.6% to $17.8 mil. Commenting on the showing, Forest President Howard Solomon noted that "Aerobid, our largest product, has continued its excellent growth aided by Aerobid-M," which was introduced last autumn. He added that the Lorcet line, "following the launch of Lorcet 10/650, also grew strongly. The growth of these products, together with the continued excellent performance of Tessalon and Esgic line give us confidence in our future growth."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel